“Efficacy of Generic Bortezomib Used as a Part of CyBorD Regimen to Achieve Complete Response in Multiple Myeloma”, ijmhs, vol. 9, no. 1, pp. 247–251, Feb. 2019, doi: 10.15520/ijmhs.v9i1.2431.